Highlights

  • Algorae Pharmaceuticals (ASX:1AI) reported AUD 3.94 million in cash at 30 June 2026.
  • Its AlgoraeRx subsidiary reported five pharmaceutical manufacturing partner agreements.
  • Two product registration dossiers had been accepted for TGA evaluation during FY26.
  • AlgoraeOS v2 screened more than 9 million potential drug–drug–cell-line combinations.

Algorae Pharmaceuticals Limited (ASX:1AI) operates a pharmaceutical supply business alongside an artificial intelligence-based drug research program. During FY26, the Melbourne-based company added manufacturing partnerships, advanced Australian medicine registration applications and expanded the number of combinations assessed by its AlgoraeOS platform. Its June-quarter cash report also recorded spending on registration, inventory and research ahead of commercial supply. At the time of writing on 19 October 2026, Algorae shares were trading at AUD 0.010, up 11.11% during the day’s trading session.

Company Business

Algorae has two related but distinct activities. The AlgoraeRx subsidiary seeks to register and distribute generic and specialty medicines in Australia and New Zealand through arrangements with manufacturers. Its target customers include hospitals, pharmacies and other institutional purchasers. Commercial delivery depends on relevant regulatory approvals, product availability and purchase orders.

Its research business uses AlgoraeOS, an AI-driven platform designed to identify potential drug combinations for laboratory assessment. Predictions produced by its models are research hypotheses, not evidence that a treatment is safe or effective in patients. The company works with the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre to test selected combinations in preclinical settings.

Recent Development

In the June 2026 quarter, AlgoraeRx signed an exclusive commercial and licensing arrangement with Zydus Lifesciences covering 10 injectable, oral and specialty pharmaceutical products. It also entered a licence and supply agreement with Torrent Pharmaceuticals for two generic prescription molecules, later expanded to three. Together with existing arrangements involving Sakar Healthcare, Dr Reddy’s Laboratories and Cadila Pharmaceuticals, the business reported five manufacturing partner agreements.

Regulatory work proceeded alongside the new contracts. By the July quarterly update, Algorae said three product dossiers had been submitted to Australia’s Therapeutic Goods Administration, with two accepted for formal evaluation. Acceptance for review is not the same as registration approval. Product sales depend on completing the relevant assessment and supply arrangements.

The company also reported that its AlgoraeOS v2 multi-anchor program had generated predictions across 18 anchor medicines. It screened more than 9 million possible drug–drug–cell-line combinations, identifying over 478,000 predictions meeting its screening thresholds and more than 6,000 combinations with predicted synergy across multiple cell lines. These outputs require further experimental testing.

In July, Algorae disclosed results from a second independent preclinical validation program, involving 24 selected medicines combined with CBD across four cancer cell models. It also received a AUD 49,109 grant to support further validation, and disclosed an NSW Health public hospital supply contract. The company has not assigned guaranteed revenue to those development milestones in its June-quarter report.

Financial Performance and Sector Context

Cash and cash equivalents totalled AUD 3.94 million at 30 June 2026, down from AUD 5.47 million at the end of March. Net cash used in operating activities during the June quarter was AUD 1.60 million, while the corresponding full-year operating cash outflow was AUD 2.60 million. The quarterly return reported no customer receipts; accordingly, contractual distribution arrangements should not be confused with recognised sales.

Within June-quarter operating expenditure, research and development accounted for AUD 590,401, product manufacturing and operating costs AUD 644,784, and staff costs AUD 264,151. Net financing inflows of AUD 63,410 partly offset operating spending. Algorae also reported an undrawn AUD 3.0 million receivables-based working capital facility with ScotPac, taking stated cash and available facility capacity to approximately AUD 6.94 million at quarter-end. A facility is not equivalent to unrestricted cash.

The company participates in markets shaped by medicine registration rules, institutional procurement and pharmaceutical manufacturing requirements. Research programs face a different assessment process: computational predictions must undergo biological testing and further development before any potential clinical use.

Risks to Consider

The main disclosed execution risks concern regulatory timing, manufacturing and inventory commitments, and the conversion of distribution agreements into actual deliveries and receipts. The business continues to spend on operating and research activities before establishing material customer cash receipts in its quarterly report. AI-predicted drug combinations may not be validated experimentally or progress to clinical development. Additional funding needs and future equity issuance also remain relevant considerations.

What to Watch Next

The next quarterly cash-flow report should clarify customer receipts, inventory investment and the use of existing funds. Other measurable milestones include TGA decisions on submitted dossiers, product orders under manufacturing and hospital supply arrangements, and further independent results from the multi-anchor AI program. Investors can also monitor whether the company draws on its working capital facility and how additional commercial launches are financed.

Key Insights

Algorae ended June 2026 with AUD 3.94 million of cash while developing a portfolio of pharmaceutical supply agreements and continuing preclinical AI research. Its near-term progress can be assessed through medicine registrations, orders and cash collections, alongside evidence from independently tested drug combinations.